Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia.

Hines P, Dover GJ, Resar LM.

Pediatr Blood Cancer. 2008 Feb;50(2):357-9.

PMID:
17253639
2.

Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy.

Resar LM, Segal JB, Fitzpatric LK, Friedmann A, Brusilow SW, Dover GJ.

J Pediatr Hematol Oncol. 2002 Dec;24(9):737-41.

PMID:
12468915
3.
5.

Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ.

Blood. 1995 Jan 1;85(1):43-9.

6.
7.

Determinants of fetal hemoglobin response to hydroxyurea.

Steinberg MH.

Semin Hematol. 1997 Jul;34(3 Suppl 3):8-14. Review.

PMID:
9317196
8.

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ.

Blood. 1997 Feb 1;89(3):1078-88.

9.

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.

Blood. 1998 Jun 15;91(12):4472-9.

10.
11.

A cautionary note regarding hydroxyurea in sickle cell disease.

Vichinsky EP, Lubin BH.

Blood. 1994 Feb 15;83(4):1124-8.

12.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

13.

Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease.

Marcus SJ, Kinney TR, Schultz WH, O'Branski EE, Ware RE.

Am J Hematol. 1997 Jan;54(1):40-6.

14.
15.

Increased HbF in sickle cell anemia is determined by a factor linked to the beta S gene from one parent.

Milner PF, Leibfarth JD, Ford J, Barton BP, Grenett HE, Garver FA.

Blood. 1984 Jan;63(1):64-72.

16.

Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.

Haynes J Jr, Obiako B, Hester RB, Baliga BS, Stevens T.

Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H379-85. Epub 2007 Nov 9.

17.

Fluctuation of fetal hemoglobin in sickle-cell anemia.

Morrison JC, Whybrew WD, Bucovaz ET, Wiser WL.

Am J Obstet Gynecol. 1976 Aug 15;125(8):1085-8.

PMID:
952305
18.

Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N.

Blood. 2002 Jun 1;99(11):3905-8.

19.

Chemotherapy to increase fetal hemoglobin in patients with sickle cell anemia.

Platt OS.

Am J Pediatr Hematol Oncol. 1985 Fall;7(3):258-60.

PMID:
2416231
20.

Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?

Powars DR, Weiss JN, Chan LS, Schroeder WA.

Blood. 1984 Apr;63(4):921-6.

Supplemental Content

Support Center